Thermo Fisher Scientific Inc. $TMO Shares Purchased by Dorsey & Whitney Trust CO LLC

Key Points

• Dorsey & Whitney Trust CO LLC has increased its stake in Thermo Fisher Scientific Inc. by 12.2%, owning 5,162 shares valued at approximately $2.57 million as of their latest SEC filing.
• Thermo Fisher Scientific reported a quarterly EPS of $5.36, surpassing estimates, and with a year-over-year revenue increase of 2.9%, reaching $10.86 billion.
• The company has announced a quarterly dividend of $0.43, with a dividend yield of 0.3% and a payout ratio of 9.95%.

Dorsey & Whitney Trust CO LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,162 shares of the medical research company's stock after acquiring an additional 560 shares during the quarter. Dorsey & Whitney Trust CO LLC's holdings in Thermo Fisher Scientific were worth $2,569,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at $25,000. Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $30,000. Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $31,000. IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the first quarter worth about $35,000. Finally, Navigoe LLC acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $494.8160 on Thursday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $186.85 billion, a P/E ratio of 28.62, a price-to-earnings-growth ratio of 2.66 and a beta of 0.74. The firm has a 50-day moving average price of $439.69 and a two-hundred day moving average price of $458.78. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the business earned $5.37 earnings per share. The company's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of analyst reports. William Blair started coverage on Thermo Fisher Scientific in a research note on Monday. They set an "outperform" rating for the company. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Finally, Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 8,000 shares of the company's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $52,340,824.30. This trade represents a 6.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,400 shares of company stock worth $8,345,792. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.